A phase Ib open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.
BO45287
This trial is No longer recruiting
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Maciej Tatarczuch